JP2023539476A5 - - Google Patents
Info
- Publication number
- JP2023539476A5 JP2023539476A5 JP2023512755A JP2023512755A JP2023539476A5 JP 2023539476 A5 JP2023539476 A5 JP 2023539476A5 JP 2023512755 A JP2023512755 A JP 2023512755A JP 2023512755 A JP2023512755 A JP 2023512755A JP 2023539476 A5 JP2023539476 A5 JP 2023539476A5
- Authority
- JP
- Japan
- Prior art keywords
- annexin
- liquid pharmaceutical
- sequence
- pharmaceutical preparation
- terminal peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20192142 | 2020-08-21 | ||
| EP20192142.6 | 2020-08-21 | ||
| PCT/EP2021/073186 WO2022038281A1 (en) | 2020-08-21 | 2021-08-20 | Annexin a1 n-terminal peptide formulations and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539476A JP2023539476A (ja) | 2023-09-14 |
| JP2023539476A5 true JP2023539476A5 (cg-RX-API-DMAC10.html) | 2024-08-27 |
Family
ID=72193322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512755A Pending JP2023539476A (ja) | 2020-08-21 | 2021-08-20 | アネキシンａ１のｎ末端ペプチド製剤及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230295255A1 (cg-RX-API-DMAC10.html) |
| EP (3) | EP4595950A3 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023539476A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116323649A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021327733A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3192030A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES3031633T3 (cg-RX-API-DMAC10.html) |
| HU (1) | HUE071875T2 (cg-RX-API-DMAC10.html) |
| PL (1) | PL4200319T3 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2022038258A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3031633T3 (en) * | 2020-08-21 | 2025-07-10 | Resother Pharma As | Annexin a1 n-terminal peptide formulations and methods |
| US20250345392A1 (en) | 2022-06-30 | 2025-11-13 | Resother Pharma A/S | Annexin a1 liquid pharmaceutical composition |
| EP4680262A1 (en) | 2023-03-13 | 2026-01-21 | Resother Pharma A/S | Annexin a1 delayed dosing |
| AU2024234229A1 (en) | 2023-03-13 | 2025-09-25 | Resother Pharma A/S | Annexin a1 administration regime |
| WO2025083394A1 (en) | 2023-10-16 | 2025-04-24 | Therakind Limited | Antimicrobial use of annexin a1 protein |
| WO2025083393A1 (en) | 2023-10-16 | 2025-04-24 | Therakind Limited | Antimicrobial use of peptides derived from annexin a1 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| BR112013032088B1 (pt) | 2011-06-15 | 2020-11-24 | Resother Pharma Aps | produtos farmacêuticos anti-inflamatórios |
| WO2013053888A1 (en) * | 2011-10-14 | 2013-04-18 | Baxter International Inc. | Protein purification by anion exchange chromatography |
| HUE052977T2 (hu) | 2014-04-22 | 2021-06-28 | Txp Pharma Gmbh | Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok) |
| CN110302176A (zh) * | 2019-06-25 | 2019-10-08 | 中国人民解放军陆军军医大学 | 一种抗炎多肽纳米药物及制备方法 |
| ES3031633T3 (en) * | 2020-08-21 | 2025-07-10 | Resother Pharma As | Annexin a1 n-terminal peptide formulations and methods |
| US20250345392A1 (en) * | 2022-06-30 | 2025-11-13 | Resother Pharma A/S | Annexin a1 liquid pharmaceutical composition |
-
2021
- 2021-08-20 ES ES21765917T patent/ES3031633T3/es active Active
- 2021-08-20 WO PCT/EP2021/073125 patent/WO2022038258A1/en not_active Ceased
- 2021-08-20 AU AU2021327733A patent/AU2021327733A1/en active Pending
- 2021-08-20 PL PL21765917.6T patent/PL4200319T3/pl unknown
- 2021-08-20 EP EP25169758.7A patent/EP4595950A3/en active Pending
- 2021-08-20 CN CN202180050871.2A patent/CN116323649A/zh active Pending
- 2021-08-20 US US18/041,727 patent/US20230295255A1/en active Pending
- 2021-08-20 CA CA3192030A patent/CA3192030A1/en active Pending
- 2021-08-20 US US18/041,729 patent/US20240041977A1/en active Pending
- 2021-08-20 HU HUE21765917A patent/HUE071875T2/hu unknown
- 2021-08-20 EP EP21765917.6A patent/EP4200319B1/en active Active
- 2021-08-20 JP JP2023512755A patent/JP2023539476A/ja active Pending
- 2021-08-20 WO PCT/EP2021/073186 patent/WO2022038281A1/en not_active Ceased
- 2021-08-20 EP EP21766151.1A patent/EP4200320A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6616931B1 (en) | Rotavirus vaccine formulations | |
| RU2011127913A (ru) | Составы, содержащие антитела | |
| CN102712677B (zh) | 脂肽组合物和相关方法 | |
| JP4902103B2 (ja) | 凍結乾燥フォームによる生物活性材料の保存 | |
| CA2272245A1 (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| US5932223A (en) | Rotavirus vaccine formulations | |
| US6403098B1 (en) | Rotavirus vaccine formulations | |
| RU2008142359A (ru) | Композиция человеческого моноклонального антитела к igf-1r | |
| RU2484847C2 (ru) | Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения | |
| EP2143440A1 (fr) | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués | |
| RU2014151424A (ru) | Термостабильные составы вакцины | |
| EP0939648B1 (en) | Rotavirus vaccine formulations | |
| WO2010146598A2 (en) | Stable, dried rotavirus vaccine, compositions and process for preparation thereof | |
| JP2013515015A5 (cg-RX-API-DMAC10.html) | ||
| US20240041977A1 (en) | Annexin a1 n-terminal peptide formulations and methods | |
| US8647634B2 (en) | Recombinant avian infectious coryza vaccine and process for preparing same | |
| JPH01279843A (ja) | 凍結乾燥ａ型肝炎ワクチン | |
| RU2020131642A (ru) | Способы и композиции, содержащие сурфактантный белок d (sp-d) | |
| JP2023526218A5 (cg-RX-API-DMAC10.html) | ||
| US9999663B2 (en) | Immunogenic formulation containing recombinant live BCG that express antigens of metapneumovirus (hMPV), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use | |
| JP2022553058A5 (cg-RX-API-DMAC10.html) | ||
| JP2023538669A5 (cg-RX-API-DMAC10.html) | ||
| KR20220034053A (ko) | 재조합 단백질의 안정적인 제형 | |
| JP2024521329A5 (cg-RX-API-DMAC10.html) | ||
| KR20260074319A (ko) | 아레나바이러스 제형, 방법 및 용도 |